408 Views | 330 Downloads
Correspondence and requests for materials should be addressed to S.G.S. (email: sarafianoss@missouri.edu)
Maritza Puray-Chavez and Philip R. Tedbury contributed equally to this work.
Author contributions: S.G.S. conceived the research; S.G.S., M.P.-C, V.Y., and P.R.T. designed experiments; M.P.-C, V.Y., D.L., O.B.U., J.J., J.J.W. performed experiments; M.P.-C., A.D.H., O.B.U., A.N.E., P.R.T., and S.G.S. analyzed data; P.R.T., M.P., V.Y., and S.G.S. wrote the paper.
All authors reviewed the manuscript prior to submission.
The authors declare no competing financial interests.
The following reagents were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pNL4–3 from Dr. Malcolm Martin; HIV-2.ST pJSP4-27/H6 from Dr. Beatrice Hahn and Dr. George Shaw; Jurkat E6-1 from Dr. Arthur Weiss; TZM-bl from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc; THP-1ATCC from Drs. Li Wu and Vineet N. KewalRamani; HIV-1 p24 Gag Monoclonal (#24-2) from Dr. Michael H. Malim; Monoclonal Antibody to HIV-1 p24 (AG3.0) from Dr. Jonathan Allan; raltegravir (Cat # 11680) from Merck and Company, Inc.; HIV-1Ba-L from Dr. Suzanne Gartner, Dr. Mikulas Popovic and Dr. Robert Gallo.
We also acknowledge Dr. Michael Parniak for the gift of the RNase H inhibitor naphthyridinone {4-[(4′-aminomethyl-1,1′-biphenyl)methyl]-1-hydroxy-1,8-naphthyridin-2-one.
This work was supported in part by grants from the National Institutes of Health (AI076119, AI100890, AI120860, GM103368 to S.G.S. and AI052014 to A.N.E.), Mizzou Advantage, and Trail to a Cure.
M.P.-C and V.Y. are supported by the Fulbright Student Program.
O.U. has received support from GM056901 and the Gus T. Ridgel Fellowship.
J.J.W. is supported by a Life Sciences Fellowship from the University of Missouri.
Technical support for the confocal microscopy was provided by Alexander Jurkevich, Molecular Cytology Core, Bond Life Sciences Center, University of Missouri.
© 2017 The Author(s).